Constipation is an unsatisfactory defecation distinguished by difficult stool passage, infrequent stools or both.
Difficult stool passage may include straining, feeling of difficulty in passing stool, incomplete evacuation, lumpy/hard stools, prolonged time to defecate, need for manual maneuver to pass stool, abdominal discomfort and feeling of anorectal blockade.
Chronic constipation is considered when symptoms of constipation have existed ≥3 months.
Symptoms of chronic constipation may be due to dysfunction of intestinal motility, visceral sensitivity, anorectal musculature or the enteric nervous system.
A 4-week treatment course of Bifidobacterium lactis NCC2818 in patients with chronic mild constipation does not appear to confer benefits for whole gut transit time and for other constipation-related outcomes, such as stool frequency and stool consistency, a study reports.
New drug applications approved by US FDA as of 01- 15 December 2018
which includes New Molecular Entities (NMEs) and new biologics. It does
not include Tentative Approvals. Supplemental approvals may have
occurred since the original approval date.
The novel local-acting ileal bile acid transporter inhibitor elobixibat helps relieve chronic constipation in the short term, with well tolerated safety profile in the long term — supporting the novel approach of increasing intracolonic bile acid concentration for treating chronic constipation, two phase III studies show.
Depression appears to be a stronger predictor of absenteeism than symptom severity in patients with chronic constipation, suggests a study, adding that depression may partly contribute to the indirect costs of chronic constipation.
Use of plecanatide in the treatment of chronic idiopathic constipation appears to induce notable improvements in bowel movement frequency, stool consistency, and straining and abdominal symptoms, with a low incidence of adverse events, according to the results of a phase III trial.
Absenteeism among patients with chronic constipation appear to have a stronger association with depression than symptom severity, according to a recent study, suggesting that a portion of the indirect costs of chronic constipation is attributable to depression.
A new study reinforces the gut-brain connection in Alzheimer’s disease (AD), untangling the complex interplay between gut and brain health that could potentially lead to new therapies targeted at manipulating the gut microbiome to treat AD.
Reducing the dose of regorafenib did little to affect the overall tolerability of the drug in patients with metastatic colorectal cancer (mCRC), according to the phase II REARRANGE* trial presented at ESMO GI 2019.